Cidara Therapeutics is a biotechnology company focused on the discovery, development and commercialization of therapeutics designed for patients facing diseases. Co. is focused on infectious diseases and oncology. Co.'s primary product candidate is rezafungin acetate, an intravenous formulation of an echinocandin antifungal. Rezafungin is being developed as a once-weekly therapy for the first-line treatment and prevention of invasive fungal infections. In addition, Co. is using its Cloudbreak® platform to develop a potential new class of drugs called drug-Fc Conjugates, which target respiratory syncytial virus, human immunodeficiency virus, and the SARS-CoV-2 strains causing COVID-19. We show 38 historical shares outstanding datapoints in our CDTX shares outstanding history coverage, used to compute CDTX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing CDTX market cap history over the course of time is important for investors
interested in comparing CDTX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of CDTX versus a peer is one thing; comparing
CDTX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like CDTX can fluctuate over the course of history.
With this page we aim to empower investors researching CDTX by allowing them to research the CDTX market cap history. |
Free CDTX Email Alerts:
Video: The Importance of Market Cap
